Dipharma Francis S.r.l.

Dipharma S.p.a.

Enichem Synthesis S.p.a

Indena S.p.a.

Wyeth

Zambon Group S.p.a.

Ministero Dell'universita E Della Ricerca Scientifica E Tecnologica

Ministero Dell 'universita'e Della Ricerca Scientifica E Technologica

Great Lakes Chemical Italia S.r.l.

Dinamite Dipharma S.p.a.

Abbreviated Dipharma S.p.a.

Zamon Group S.p.a.

Lundbeck Pharmaceuticals, Italy

Pietro Allegrini

Gabriele Razzetti

Graziano Castaldi

Emanuele Attolino

Giuseppe Barreca

Luciana Crisci

Vittorio Lucchini

Alberto Bologna

Simone Mantegazza

Giorgio Soriato

Andrea Gambini

Vincenzo Cannata

Nereo Nodari

Marcello Rasparini

Vincenzo Malatesta

Roberto Rossi

Livius Cotarca

Marco Villa

Massimo Verzini

Roberto Brescello

Renzo Graziosi

Caterina Napoletano

Lino Colombo

Fiorenzo Renzi

Daniele Ciceri

Chiara Vladiskovic

Tiziano Scubla

Nicola Sardone

Marco Artico

Paolo Andreella

Davide Rossi

Fabio Bassan

Sergio Riva

Mario Michieletti

Francesco Tasinato

Marco Demo

Dario Pastorello

Andrea Bonetti

Marco Molinari

Stefano Luca Giaffreda

Paola Fassi

Franco Rivetti

Maurizio Paiocchi

Aldo Belli

Claudio Gagliardi

Kadum A Ali

Domenico Magrone

Alessandro Restelli

Antonio Tarquini

Federico Peterlongo

Fausto Gorassini

Laura Russo

Gaetano Marchioro

Maurizio Ricotti

Davide Berlanda

Katiuscia Arrighi

Gianpiero Ventimiglia

Mauro Ercoli

Luca Giannotti

Giancarlo Verardo

Anna Bernardi

Fabio Donzelli

Paola Geatti

Nicoletta Toniutti

Enrico Mariotti

Gianluca Galdi

Luca Senaldi

Eleonora Porta

Alessandro Rosi

Elena Rossi

Eliana Rocchini

Ilaria Mormino

Alessandro Andreani

Gianmaria Dell'Anna

Marco Curzi

Andrea Finco

Elena Dichiarante

Alex Petrolati

Malama K Chibwe

Enrico Modena

Shridhar G Gangolli

Carl E Longfellow

Mauro Mittino

Michele Scarpellini

Gianpiero Ventimigla

Gianmaria Dell'anna

Marco Brusasca

Giuseppe D'Arienzo

Maurizio Taddei

Diletta Naldini

The invention relates to a process for the preparation of colchicine 1 from colchicoside 2 which comprises enzymatic conversion of colchicoside 2 to 3-O-demethylcolchicine 3, wherein the enzyme used is a cellulase. According to another aspect of the invention, 3-O-demethylcolchicine 3 can be converted to colchicine 1 using an alkylating agent. The invention also relates to a process for enriching the colchicine 1 content of extracts from plants belonging to the Colchicaceae family containing colchicine 1, colchicoside 2 and 3-O-demethylcolchicine 3, which comprises conversion by means of a colchicoside 2 cellulase to 3-O-demethylcolchicine 3, followed by conversion of 3-O-demethylcolchicine 3 to colchicine 1 using an alkylating agent.

Semisynthetic process for the preparation of colchicine

The invention relates to a process for the preparation of Melphalan (4-[bis(2-chloroethyl)amino]-L-phenylalanine of formula (I) The invention also provides novel intermediates useful for the preparation of Melphalan.

Process for the synthesis of melphalan

The invention relates to a process for the preparation of Melphalan (4-[bis(2-5 chloroethyl)amino]-L-phenylalanine of formula (I) said process comprising the reaction of a 4-amino-L-phenylalanine protected at the carboxy and amino aminoacidic groups with an agent able to convert the aromatic amino group into a group of formula: &#x2014;N(CHCHOS(O)O&#x2014;), wherein n is 1 or 2 followed by conversion of the &#x2192;N(CHCHOS(O)O&#x2014;)group into a &#x2014;N(CHCHCl)group. The invention also provides novel intermediates useful for the preparation of Melphalan.

Process for the synthesis of Melphalan

The present invention relates to a process for the preparation of Lenvatinib of formula (I) from 4-amino-3-chloro-phenol and 4-chloro-7-methoxyquinoline-6-carboxamide.

Process for the preparation of Lenvatinib

The present invention provides novel crystalline forms of 4-[3-Chloro-4-(N'-cyclopropylureido)phenoxy]-7-methoxyquinoline-6-carboxamide methanesulfonate, as well as methods for their preparation.

Crystal forms of lenvatinib

Disclosed are solid forms of ingenol 3-(3,5-diethylisoxazole-4-carboxylate) selected from an amorphous form or a crystalline anhydrous form. Also disclosed are solid solvates of ingenol 3-(3,5-diethylisoxazole-4-carboxylate) selected from an acetone solvate, a dimethylcarbonate solvate, an isopropyl ether solvate, an acetonitrile solvate, a toluene solvate, a mesitylene solvate, a nitromethane solvate, a dichloromethane/heptane solvate and an ethyl acetate solvate, for use as intermediates.

Solid forms of ingenol 3-(3,5-diethylisoxazole-4-carboxylate) and method for preparing the same

Substantially stable to degradation Fesoterodine fumarate, a process for its preparation and a process for the synthesis of specific degradation impurities of Fesoterodine fumarate are disclosed.

Antimuscarinic compound having a low content of impurities

The present invention relates to novel crystalline forms of vortioxetine hydrobromide, in particular three crystalline forms, a process for their preparation, a pharmaceutical composition containing said novel crystalline forms, and a process for the purification of vortioxetine or a salt thereof, comprising the formation of one or more of the novel crystalline forms of vortioxetine hydrobromide described herein.

Crystalline forms of an antidepressant compound

The present invention relates to a process for the preparation of 1-[2-(2,4-dimethylphenylsulphanyl)phenyl]piperazine of formula (I), also known as vortioxetine, salts thereof, and intermediates useful for its synthesis.

Process for the preparation of an antidepressant and the intermediates thereof

Process for the preparation of 2-phenyl-2-methyl propanoic acid derivatives, useful as intermediates in the preparation of fexofenadine hydrochloride.

Process for the purification of 2-phenyl-2-methyl-propanoic acid derivatives

Process for the preparation of known sulfonamides having antibacterial activity applicable on industrial scale, which allows their production in high yields and purity, comprising in particular the step of nucleophile aromatic substitution and oxidation in suitable conditions.

Process for the preparation of sulfonamide compounds

The application discloses a process for the preparation of 5-deoxy-L-arabinose of formula (VI); comprising the conversion of a compound of formula (XII); wherein n is 0, 1 or 2; which can be used as intermediate for the synthesis of sapropterin. 

Process for the preparation of pteridine derivatives

A process for the preparation of (R)-2-(3-diisopropylamino-1-phenylpropyl)-4-(hydroxymethyl)-phenol isobutyrate (Fesoterodine) or a pharmaceutically acceptable salt thereof having low content in impurities.

Process for the preparation of fesoterodine or a salt thereof

The present invention relates to methods of preparing polymorphic Form A of bazedoxifene acetate and polymorphic Form A prepared by such methods.

Methods of preparing polymorphic form A of bazedoxifene acetate

A process for the preparation of (R)-2-(3-diisopropylamino-1-phenylpropyl)-4-(hydroxymethyl)-phenol isobutyrate (Fesoterodine), its (S)-enantiomer, and novel intermediates useful in the synthesis.

Process for the preparation of fesoterodine

Growing community of inventors

San Donato Milanese, Italy

Pietro Allegrini